Recent 8-K filings for MGTX

• September 23, 2026, 8:12 AM ET leadership materiality 0.40 neutral item 5.02item 7.01item 9.01 ◈ executive_change

  MeiraGTx appoints Alan M. Sebulsky to Board as Class I director effective Sept 23, 2026

  Sebulsky, Managing Member of Apothecary Capital, joins as Class I director with term expiring at 2028 annual meeting.

• August 13, 2026, 8:05 AM ET earnings materiality 0.90 positive item 2.02item 9.01

  MeiraGTx Q2 net income $160.7M; bota-vec acquired, $400M Oberland deal, BTD for AAV2-hAQP1

  Q2 net income $160.7M ($1.76 basic EPS) vs net loss $38.8M in Q2 2025; revenue from services and licenses surged.

• July 7, 2026, 7:42 AM ET other material materiality 0.85 positive item 1.01item 1.02item 2.03item 3.02item 7.01item 9.01

  MeiraGTx secures up to $400M from Oberland Capital in royalty and equity deal

  Initial $135M funded: $125M in exchange for low single-digit capped royalties on three products, plus $10M equity investment at $10.52/share.

• June 15, 2026, 4:37 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×2

  MeiraGTx shareholders elect three Class II directors and ratify Ernst & Young as auditor

  Annual meeting held June 11, 2026; 75,326,022 shares (81.4%) represented.

• May 14, 2026, 8:06 AM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  MeiraGTx Q1 net loss $46.3M; reacquires bota-vec from J&J; raises $100M

  Net loss attributable to ordinary shareholders was $46.3M ($0.57 per share) for Q1 2026, vs $40.0M ($0.51) in Q1 2025.

• April 24, 2026, 7:59 PM ET M&A materiality 0.90 positive item 1.01item 9.01 ◈ Material Agreements

  MeiraGTx closes initial $200M Hologen collaboration; Hologen to own 70% of neuro JV

  Completed initial closing of strategic collaboration with Hologen on April 20, 2026; Hologen provided $200M upfront cash payment.

• April 16, 2026, 7:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  MeiraGTx reports positive 3-year Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia

  62% of patients had ≥10-point XQ improvement at 36 months; average 17-point improvement maintained from 12 months.

• April 16, 2026, 7:59 PM ET M&A materiality 0.90 positive item 1.01item 1.02item 2.01item 7.01item 8.01item 9.01 ◈ Material Agreements ×2◈ M&A Transactions

  MeiraGTx acquires bota-vec gene therapy from Janssen for XLRP treatment

  MeiraGTx paid $25M upfront to Janssen for bota-vec, with a potential $50M milestone upon US approval and $250M sales threshold.

• April 16, 2026, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements

  MeiraGTx prices $100M public offering of 11.1M shares at $9.00 each; net proceeds ~$93.3M

  11,111,111 ordinary shares at $9.00/sh; net proceeds ~$93.3M after underwriting discounts and expenses.

• March 26, 2026, 7:59 PM ET earnings materiality 0.85 positive item 1.01item 2.02item 2.03item 9.01 ◈ Debt Financings◈ Earnings Releases◈ Material Agreements

  MeiraGTx: FDA Breakthrough for xerostomia, FY2025 net loss $114.2M, $200M Hologen JV

  FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia; RMAT also granted.

• January 2, 2026, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements

  MeiraGTx repurchases 2.3M shares from Perceptive Master Fund for $18.2M at $7.91 per share

  Bought 2,300,000 ordinary shares from Perceptive Life Sciences Master Fund at VWAP of $7.91, aggregate $18.2M.

• November 13, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  MeiraGTx Q3 net loss $50.5M; enters ophthalmology collaboration with Lilly for $75M upfront

  Collaboration with Lilly: upfront $75M, eligible for >$400M milestones and tiered royalties on ocular programs.

• November 10, 2025, 6:59 PM ET M&A materiality 0.85 positive item 1.01item 7.01item 9.01

  MeiraGTx licenses AAV-AIPL1 and gene therapy tools to Lilly for $75M upfront, up to $400M milestones

  Upfront payment of $75M; eligible for over $400M in total milestones, including up to $135M near-term.

• August 14, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  MeiraGTx Q2 net loss narrows to $38.8M; FDA alignment on RIX pivotal study, RMAT for Parkinson's

  Net loss $38.8M ($0.48/sh) vs $48.6M ($0.76/sh) in Q2 2024; cash $32.2M at June 30, 2025.

• June 26, 2025, 7:59 PM ET M&A materiality 0.65 positive item 7.01

  MeiraGTx receives UK FDI clearances for Hologen deal; closing expected July 2025

  UK foreign direct investment clearances obtained for proposed transactions with Hologen Limited.

• June 17, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.07

  MeiraGTx annual meeting elects director, ratifies auditor

  Director Thomas E. Shenk elected with 40.3M votes for, 9.1M withheld, 9.9M broker non-votes.

• May 13, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  MeiraGTx Q1 net loss $40.0M; announces $200M Hologen AI collaboration, RMAT for AAV-GAD

  Q1 net loss $40.0M ($0.51/share) vs $20.4M ($0.32) YoY; revenue $1.9M; cash $66.5M.

• May 9, 2025, 7:59 PM ET regulatory materiality 0.65 positive item 7.01item 9.01

  FDA grants RMAT designation to MeiraGTx's AAV-GAD for Parkinson's disease

  RMAT designation based on data from three clinical studies (Phase 1 n=12, Phase 2 n=45, dose-ranging n=14).

• April 4, 2025, 7:59 PM ET other material materiality 0.30 neutral item 1.01item 1.02

  MeiraGTx enters 7yr7mo lease for 14,235 sq ft NYC lab; terminates prior sublease

  New lease with ARE-East River Science Park for lab/office space at $111/sq ft/yr, 3% annual escalations.

• March 13, 2025, 7:59 PM ET M&A materiality 0.80 positive item 1.01item 2.02item 7.01item 9.01

  MeiraGTx enters collaboration with Hologen AI: $200M upfront, $230M JV funding for AAV-GAD

  Received $200M upfront cash from Hologen; forming JV Hologen Neuro AI Ltd.

• December 9, 2024, 6:59 PM ET regulatory materiality 0.70 positive item 8.01item 9.01

  MeiraGTx granted FDA RMAT designation for AAV2-hAQP1 in Grade 2/3 radiation-induced xerostomia

  FDA's RMAT designation includes Fast Track, Breakthrough Therapy benefits and potential Priority Review and accelerated approval.

• November 13, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  MeiraGTx secures MHRA pathway for AAV-AIPL1 approval without further studies; Q3 net loss $39.3M

  AAV-AIPL1 MAA under exceptional circumstances agreed with MHRA; no further clinical studies required for UK approval.

• October 15, 2024, 7:59 PM ET other material materiality 0.70 positive item 7.01item 8.01item 9.01

  MeiraGTx reports positive Phase 2 data for AAV-GAD in Parkinson's; 18-point UPDRS improvement in high-dose group

  AAV-GAD met primary safety endpoint; no SAEs related to treatment in 14-patient bridging study.

• August 13, 2024, 7:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  MeiraGTx closes public offering of 12.5M shares at $4.00, netting $48.3M

  Public offering of 12,500,000 ordinary shares at $4.00/share completed August 13, 2024; net proceeds ~$48.3M.

• August 12, 2024, 7:59 PM ET other material materiality 0.80 negative item 2.02item 9.01

  MeiraGTx reports Q2 net loss of $48.6M and $50M offering led by Sanofi

  Net loss $48.6M ($0.76/share) vs $29.6M ($0.53) in Q2 2023; service revenue $0.3M, no license revenue.

• June 10, 2024, 7:59 PM ET other materiality 0.00 neutral item 5.07

  MeiraGTx 2024 AGM results: directors elected, say-on-pay approved, auditor ratified

  Three Class III directors elected: Forbes (99.8% cast, 49.6M for), Harris (99.5%), Mendoza (99.7%).

• May 9, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  MeiraGTx Q1 net loss narrows to $20.4M; receives $50M milestone from Janssen

  Net loss attributable to shareholders $20.4M ($0.32 per share) vs $30.4M ($0.62) in Q1 2023.

• April 16, 2024, 7:59 PM ET leadership materiality 0.20 neutral item 5.02

  MeiraGTx amends prior 8-K to disclose Dr. Debra Yu's committee appointments

  Debra Yu, M.D., joined the Board on April 25, 2022; this amendment adds committee assignments.

• March 14, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  MeiraGTx reports FY2023 net loss of $84M, down 35% YoY; Janssen deal yields $50M milestone

  Net loss $84.0M ($1.49/share) vs $129.6M ($2.87) in 2022; license revenue $14.0M.

• February 13, 2024, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  MeiraGTx receives $50M milestone from Janssen for bota-vec Phase 3 extension study

  $50M milestone triggered by initiation of LUMEOS extension study for bota-vec (XLRP gene therapy).

• December 21, 2023, 6:59 PM ET M&A materiality 0.80 positive item 1.01item 1.02item 2.01item 2.03item 7.01item 9.01 ◈ Material Agreements ×3◈ M&A Transactions

  MeiraGTx sells bota-vec rights to J&J's Janssen for up to $415M; $130M upfront/near-term

  Upfront $65M at signing; additional $50M expected Q1 2024 and $15M later, totaling $130M near-term.

• November 14, 2023, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  MeiraGTx reports Q3 net loss $44.3M; Sanofi invests $30M at $7.50/share

  Sanofi purchased $30M of ordinary shares at $7.50/share; ROFN for Riboswitch platform on CNS, I&I, metabolic targets including GLP-1 and Xerostomia.

• October 30, 2023, 7:59 PM ET other material materiality 0.75 positive item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements ×2

  MeiraGTx announces $30M Sanofi investment at $7.50/share; exploring additional strategic transactions

  Sanofi subsidiary purchased 4M ordinary shares at $7.50 each for gross proceeds of $30M; shares subject to 18-month lock-up and standstill for 24 months.

• August 10, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 1.01item 2.02item 2.03item 9.01 ◈ Debt Financings◈ Earnings Releases◈ Material Agreements

  MeiraGTx Q2 net loss $29.6M; Phase 3 XLRP trial enrollment surpassed; secures $25M note amendment

  Q2 2023 net loss $29.6M ($0.53/share) vs $34.0M ($0.76) YoY; license revenue $3.5M (down from $10.8M).

• June 12, 2023, 7:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×2

  MeiraGTx annual meeting results: all director nominees elected, auditor ratified

  Turnout of 77.3% (37,669,017 shares) at annual meeting on June 8, 2023.

• May 11, 2023, 7:59 PM ET earnings materiality 0.50 neutral item 2.02item 9.01 ◈ Earnings Releases

  MeiraGTx Q1 net loss $30.4M; raises $60M PIPE; BLA on track for 2024

  Net loss $30.4M ($0.62/share) vs $31.0M ($0.70) in Q1 2022; cash $68.8M at March 31, 2023.

• May 9, 2023, 7:59 PM ET other material materiality 0.80 neutral item 1.01item 3.02 ◈ Material Agreements

  MeiraGTx raises $62M in private placement at $5.75/share

  Sold 10,773,913 ordinary shares at $5.75/share for gross proceeds of ~$62M; closed May 5, 2023.

• April 26, 2023, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 ◈ executive_change

  Director Arnold J. Levine resigns from MeiraGTx board for health reasons

  Arnold J. Levine, Ph.D. resigned from the Board effective April 21, 2023.

• March 14, 2023, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01 ◈ Earnings Releases

  MeiraGTx reports 2022 net loss $129.6M; pipeline advances toward 2024 BLA

  Net loss of $129.6M ($2.87/share) vs $79.6M in 2021; revenue $15.9M (down from $37.7M on lower milestone payments).

• March 10, 2023, 6:59 PM ET other material materiality 0.60 positive item 7.01

  MeiraGTx discloses no exposure to Silicon Valley Bank

  Company does not hold cash deposits or securities with Silicon Valley Bank.

• November 10, 2022, 6:59 PM ET earnings materiality 0.65 neutral item 1.01item 2.02item 3.02item 9.01 ◈ Earnings Releases◈ Material Agreements

  MeiraGTx reports Q3 2022 net loss $37.3M; receives $25M investment from JJDC

  Net loss of $37.3M ($0.83 per share) vs $25.9M ($0.59) in Q3 2021.

• August 11, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  MeiraGTx Q2 net loss $34M; positive XLRP gene therapy data; extends cash runway to Q4 2024

  Net loss of $34.0M ($0.76/share) vs $20.1M ($0.46) in Q2 2021; license revenue up to $10.8M.

• August 4, 2022, 7:59 PM ET debt materiality 0.75 positive item 1.01item 2.03item 3.02item 8.01item 9.01

  MeiraGTx secures up to $100M debt financing from Perceptive, collateralized by manufacturing facilities

  $75M initial term loan from Perceptive Advisors, with option for additional $25M; interest at 10% + SOFR, maturity Aug 2026.

• June 27, 2022, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

  Director Joel S. Marcus resigns from MeiraGTx board, effective immediately

  Joel S. Marcus resigned from Board of Directors and all committees, effective June 27, 2022.

• June 9, 2022, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  MeiraGTx shareholders elect three Class I directors, ratify EY as auditor

  75.2% of outstanding ordinary shares were present or represented at June 7, 2022 AGM.

• May 12, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  MeiraGTx Q1 net loss widens to $0.70 per share; Phase 3 XLRP trial actively dosing

  Net loss of $31.0M ($0.70 per share) vs $23.6M ($0.54) in Q1 2021; R&D spend rose to $23.1M.

• April 27, 2022, 7:59 PM ET leadership materiality 0.30 neutral item 5.02item 7.01item 9.01 ◈ executive_change

  MeiraGTx appoints Debra Yu, MD to Board of Directors

  Dr. Yu appointed effective April 25, 2022 as Class II director; term expires at 2023 annual meeting.

• March 10, 2022, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  MeiraGTx reports 2021 net loss of $79.6M; cash $137.7M; pipeline advances

  Net loss $79.6M ($1.80/share) vs $58.0M ($1.54/share) in 2020; license revenue rose to $37.7M from $15.6M.

• December 7, 2021, 6:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  MeiraGTx reports positive Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia; 6/7 patients improved

  6 of 7 participants achieved clinically meaningful improvement in xerostomia symptoms on two validated PRO measures.

• November 10, 2021, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  MeiraGTx Q3 net loss $25.9M ($0.59/sh); cash $143.6M; R&D spend jumps

  Net loss $25.9M ($0.59 loss per share) vs $6.4M ($0.17) YoY; license revenue $6.9M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event earnings

23 positive 3 negative 24 neutral

source · MGTX on sec.gov